Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Body Mass Index
100%
Lymphoma Patients
100%
Survival Outcomes
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Follicular Lymphoma
71%
Hodgkin Lymphoma
71%
Clinical Outcomes
42%
Overall Survival
42%
Failure-free Survival
42%
Phase I Trial
28%
Patient Characteristics
14%
Clinical Characteristics
14%
Clinical Factors
14%
R-CHOP
14%
Prognosis Factors
14%
Favorable Prognosis
14%
Non-associated
14%
Cox Model
14%
High Body Mass Index
14%
Subset Analysis
14%
Medicine and Dentistry
Body Mass Index
100%
Diffuse Large B-Cell Lymphoma
87%
Follicular Lymphoma
62%
Hodgkin's Lymphoma
62%
Overall Survival
37%
Failure Free Survival
37%
Clinical Trial
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Proportional Hazards Model
12%
Obesity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Hodgkin Disease
71%
Follicular Lymphoma
71%
Overall Survival
42%
Failure Free Survival
42%
Clinical Trial
28%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%
Obesity
14%
Biochemistry, Genetics and Molecular Biology
Body Mass
100%
B Cell
87%
Overall Survival
37%
Failure Free Survival
37%
Clinical Trial
25%
Immunology and Microbiology
Body Mass
100%
B Cell
87%
Overall Survival
37%
Failure Free Survival
37%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
12%